$186.14
1.18% today
NYSE, Sep 19, 05:45 pm CET
ISIN
US0758871091
Symbol
BDX

Becton, Dickinson & Stock price

$188.37
-6.63 3.40% 1M
-43.75 18.85% 6M
-38.50 16.97% YTD
-43.22 18.66% 1Y
-62.89 25.03% 3Y
-37.72 16.68% 5Y
+53.51 39.67% 10Y
+136.31 261.82% 20Y
NYSE, Closing price Thu, Sep 18 2025
+0.80 0.43%

Key metrics

Basic
Market capitalization
$54.0b
Enterprise Value
$72.6b
Net debt
$18.6b
Cash
$757.0m
Shares outstanding
286.6m
Valuation (TTM | estimate)
P/E
33.7 | 13.0
P/S
2.5 | 2.4
EV/Sales
3.4 | 3.3
EV/FCF
28.5
P/B
2.1
Dividends
DPS
$4.16
Yield 1Y | 5Y
2.2% | 1.5%
Growth 1Y | 5Y
9.5% | 6.2%
Payout 1Y | 3Y
64.9% | 65.3%
Increased
25 Years
Financials (TTM | estimate)
Revenue
$21.4b | $22.1b
EBITDA
$5.4b | $6.5b
EBIT
$3.0b | $5.4b
Net Income
$1.6b | $4.2b
Free Cash Flow
$2.6b
Growth (TTM | estimate)
Revenue
7.9% | 9.4%
EBITDA
4.0% | 24.3%
EBIT
2.5% | 86.7%
Net Income
13.7% | 144.2%
Free Cash Flow
-20.8%
Margin (TTM | estimate)
Gross
45.1%
EBITDA
25.4% | 29.2%
EBIT
14.1%
Net
7.5% | 18.9%
Free Cash Flow
11.9%
Financial Health
Equity Ratio
45.2%
Return on Equity
6.6%
ROCE
6.5%
ROIC
-
Debt/Equity
0.8
More
EPS
$5.6
FCF per Share
$8.9
Short interest
1.6%
Employees
74k
Rev per Employee
$270.0k
Show more

Is Becton, Dickinson & a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,012 stocks worldwide.

Becton, Dickinson & Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Becton, Dickinson & forecast:

8x Buy
44%
10x Hold
56%

Analyst Opinions

18 Analysts have issued a Becton, Dickinson & forecast:

Buy
44%
Hold
56%

Financial data from Becton, Dickinson &

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
21,386 21,386
8% 8%
100%
- Direct Costs 11,745 11,745
8% 8%
55%
9,641 9,641
7% 7%
45%
- Selling and Administrative Expenses 5,167 5,167
9% 9%
24%
- Research and Development Expense 1,244 1,244
6% 6%
6%
5,440 5,440
4% 4%
25%
- Depreciation and Amortization 2,419 2,419
6% 6%
11%
EBIT (Operating Income) EBIT 3,021 3,021
3% 3%
14%
Net Profit 1,606 1,606
14% 14%
8%

In millions USD.

Don't miss a Thing! We will send you all news about Becton, Dickinson & directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Becton, Dickinson & Stock News

Neutral
GlobeNewsWire
about 3 hours ago
Fluorescence Cell Market (2024 - 2034) Report by Towards Healthcare, a sister firm of Precedence Research Fluorescence Cell Market (2024 - 2034) Report by Towards Healthcare, a sister firm of Precedence Research
Neutral
PRNewsWire
2 days ago
FRANKLIN LAKES, N.J. , Sept. 17, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the placement of the 1,000th BD Rhapsody™ System, a flagship instrument for single-cell multiomics analysis, at Addenbrooke's Hospital of the University of Cambridge, United Kingdom.
Neutral
Forbes
15 days ago
On 9/8/25, Alphabet, Becton, Dickinson, and Rogers Communications will all trade ex-dividend for their respective upcoming dividends. Alphabet will pay its quarterly dividend of $0.21 on 9/15/25, Becton, Dickinson will pay its quarterly dividend of $1.04 on 9/30/25, and Rogers Communications will pay its quarterly dividend of $0.50 on 10/3/25.
More Becton, Dickinson & News

Company Profile

Becton, Dickinson & Co. is a medical technology company. The firm engages in the development, manufacture and sale of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. It operates through the following segments: BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via Homecare business. The company was founded in 1897 and is headquartered in Franklin Lakes, NJ.

Head office United States
CEO Thomas Polen
Employees 74,000
Founded 1897
Website www.bd.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today